{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:49:55Z","timestamp":1787878195705,"version":"build-2784847793"},"reference-count":22,"publisher":"American Diabetes Association","issue":"9","license":[{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"name":"Novo Nordisk A\/S, Denmark"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>The Semaglutide and Walking Capacity in People with Symptomatic Peripheral Artery Disease and Type 2 Diabetes (STRIDE) trial (NCT04560998) showed that once-weekly subcutaneous semaglutide 1.0 mg significantly improved functional outcomes, symptoms, and quality of life in individuals with symptomatic peripheral artery disease (PAD) and type 2 diabetes. Whether these benefits are consistent across diabetes-related characteristics remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>The primary outcome was the ratio to baseline (ETR) in maximum walking distance (MWD), with pain-free walking distance (PFWD) as a key secondary end point. Both were measured at 52 weeks using a constant load treadmill. Subgroup analyses were performed by diabetes duration, BMI, HbA1c, and diabetes medications. A mixed model for repeated measurements was used, incorporating treatment, region, and subgroup as fixed factors, and baseline value as covariate, along with the treatment-by-subgroup interaction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Among 792 participants (median diabetes duration 12.2 years, HbA1c 7.1%, and BMI 28.7 kg\/m2), 35.1% used sodium\u2013glucose cotransporter 2 inhibitors and 31.7% used insulin. Semaglutide significantly improved MWD regardless of diabetes duration (ETR of 1.15 vs. 1.13 for &amp;lt;10 vs. \u226510 years, P = 0.80), BMI (1.12 vs. 1.16 for &amp;lt;30 vs. \u226530 kg\/m2, P = 0.58), HbA1c (1.13 for &amp;lt;7% and \u22657%, P = 0.99), or medication use. Semaglutide also improved PFWD across subgroups (P &amp;gt; 0.1 for all interactions). BMI reduction correlated weakly with MWD improvements and was more pronounced in the control individuals with higher baseline BMI. Safety outcomes were consistent across subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Semaglutide improved walking function in people with PAD and type 2 diabetes, including individuals without obesity and those with well-controlled HbA1c. Benefits were consistent across BMI and HbA1c categories, supporting effectiveness beyond weight or glycemic changes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title\/>\n                  <\/jats:sec>","DOI":"10.2337\/dc25-1082","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T14:31:49Z","timestamp":1750516309000},"page":"1529-1535","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":15,"title":["Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial"],"prefix":"10.2337","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1269-3580","authenticated-orcid":false,"given":"Neda","family":"Rasouli","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Metabolism and Diabetes, University of Colorado School of Medicine, and VA Eastern Colorado Health Care 1 , Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ecenur","family":"Guder Arslan","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg 2 , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei-Mircea","family":"Catarig","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg 2 , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Houlind","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, Lillebaelt Hospital 3 , Kolding, Denmark"},{"name":"Department of Regional Health Research, University of Southern Denmark 4 , Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Ludvik","sequence":"additional","affiliation":[{"name":"1st Medical Department and Karl Landsteiner Institute of Obesity and Metabolic Disorders, Landstrasse Clinic 5 , Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joakim","family":"Nordanstig","sequence":"additional","affiliation":[{"name":"Institute of Medicine, Department of Molecular and Clinical Medicine, University of Gothenburg 6 , Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3510-9594","authenticated-orcid":false,"given":"Harald","family":"Sourij","sequence":"additional","affiliation":[{"name":"Cardiometabolic Trials Unit, Division of Endocrinology and Diabetology, Medical University of Graz 7 , Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Thomas","sequence":"additional","affiliation":[{"name":"Novo Nordisk GBS India 8 , Bangalore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Surgery, St. Michael\u2019s Hospital and University of Toronto 9 , Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc P.","family":"Bonaca","sequence":"additional","affiliation":[{"name":"CPC Clinical Research and Division of Cardiology, University of Colorado School of Medicine 10 , Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2025,6,21]]},"reference":[{"key":"2026061714351474700_B1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","article-title":"Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1\u00b79 million people","volume":"3","author":"Shah","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026061714351474700_B2","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1161\/CIR.0000000000001005","article-title":"Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American Heart Association","volume":"144","author":"Criqui","year":"2021","journal-title":"Circulation"},{"key":"2026061714351474700_B3","doi-asserted-by":"crossref","first-page":"827","DOI":"10.4239\/wjd.v12.i6.827","article-title":"Diabetes and peripheral artery disease: a review","volume":"12","author":"Soyoye","year":"2021","journal-title":"World J Diabetes"},{"key":"2026061714351474700_B4","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1007\/s13300-024-01606-6","article-title":"Epidemiology and burden of peripheral artery disease in people with type 2 diabetes: a systematic literature review","volume":"15","author":"Verma","year":"2024","journal-title":"Diabetes Ther"},{"key":"2026061714351474700_B5","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ejvs.2017.07.018","article-title":"Editor\u2019s Choice - 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS)","volume":"55","author":"Aboyans","year":"2018","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2026061714351474700_B6","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1161\/CIRCRESAHA.116.303849","article-title":"Epidemiology of peripheral artery disease","volume":"116","author":"Criqui","year":"2015","journal-title":"Circ Res"},{"key":"2026061714351474700_B7","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4065\/mcp.2010.0133","article-title":"Peripheral artery disease: current insight into the disease and its diagnosis and management","volume":"85","author":"Olin","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"2026061714351474700_B8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/1477-7525-11-175","article-title":"Burden of peripheral arterial disease in Europe and the United States: a patient survey","volume":"11","author":"Marrett","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"2026061714351474700_B9","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.jacc.2022.02.031","article-title":"Impact of polyvascular disease and diabetes on limb and cardiovascular risk in peripheral artery disease","volume":"79","author":"Behan","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026061714351474700_B10","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.2337\/dc25-S010","article-title":"10. Cardiovascular disease and risk management: Standards of Care in Diabetes\u20142025","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"key":"2026061714351474700_B11","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026061714351474700_B12","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026061714351474700_B13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/oby.23621","article-title":"Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics","volume":"31","author":"Lingvay","year":"2023","journal-title":"Obesity (Silver Spring)"},{"key":"2026061714351474700_B14","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.2337\/dc18-1094","article-title":"The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: results from the LEADER trial","volume":"41","author":"Dhatariya","year":"2018","journal-title":"Diabetes Care"},{"key":"2026061714351474700_B15","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/dom.14890","article-title":"Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses","volume":"25","author":"Kosiborod","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026061714351474700_B16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"2026061714351474700_B17","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/ehjcvp\/pvae071","article-title":"Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes","volume":"10","author":"Bonaca","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026061714351474700_B18","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","article-title":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial","volume":"405","author":"Bonaca","year":"2025","journal-title":"Lancet"},{"key":"2026061714351474700_B19","doi-asserted-by":"crossref","first-page":"421","DOI":"10.7326\/0003-4819-141-6-200409210-00007","article-title":"Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus","volume":"141","author":"Selvin","year":"2004","journal-title":"Ann Intern Med"},{"key":"2026061714351474700_B20","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s13679-023-00510-7","article-title":"Obesity and peripheral artery disease: current evidence and controversies","volume":"12","author":"Lempesis","year":"2023","journal-title":"Curr Obes Rep"},{"key":"2026061714351474700_B21","doi-asserted-by":"crossref","first-page":"H1159","DOI":"10.1152\/ajpheart.00574.2023","article-title":"GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage","volume":"326","author":"Park","year":"2024","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026061714351474700_B22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/48\/9\/1529\/833036\/dc251082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/48\/9\/1529\/833036\/dc251082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T18:35:22Z","timestamp":1781721322000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/48\/9\/1529\/160652\/Benefit-of-Semaglutide-in-Symptomatic-Peripheral"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,21]]},"references-count":22,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,6,21]]},"published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc25-1082","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,21]]}}}